Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Oncotarget
|
August 17, 2016
Phosphatidylinositide 3-kinase (PI3K) and PI3K-related kinase (PIKK) activity contributes to radioresistance in thyroid carcinomas
Natalie Burrows, Joseph Williams, Brian A Telfer, et al.
Plos One
|
August 12, 2016
The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy
Simon J A van Kuijk, Roben G Gieling, Raymon Niemans, et al.
International Journal of Cancer
|
January 7, 2014
A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models
Amy L Adlard, Simon J Dovedi, Brian A Telfer, et al.
Plos One
|
March 3, 2018
High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma
Kenny Kwok-Hei Yu, Jessica T Taylor, Omar N Pathmanaban, et al.
Bioengineering (Basel, Switzerland)
|
May 27, 2026
Deep Learning-Based Tracking of Neurovascular Features Toward Semi-Automated Ultrasound-Guided Peripheral Nerve Blocks by Non-Specialists
Lars A Gjesteby, Alec Carruthers, Joshua Werblin, et al.
Cancer Research Communications
|
December 5, 2022
Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1/S cell cycle transition
Jingwei Zhang, Adam J Pearson, Nitin Sabherwal, et al.
Plos One
|
February 18, 2015
Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself
Cian M McCrudden, Martin G O'Rourke, Kim E Cherry, et al.
Cell Reports
|
June 22, 2022
Oxidative stress from DGAT1 oncoprotein inhibition in melanoma suppresses tumor growth when ROS defenses are also breached
Daniel J Wilcock, Andrew P Badrock, Chun W Wong, et al.
Nature Communications
|
September 26, 2023
PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models
Chun Wai Wong, Christos Evangelou, Kieran N Sefton, et al.
Scientific Reports
|
March 17, 2022
Author Correction: Detection of COVID-19 using multimodal data from a wearable device: results from the first TemPredict Study
Ashley E Mason, Frederick M Hecht, Shakti K Davis, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Oncotarget
|
August 17, 2016
Phosphatidylinositide 3-kinase (PI3K) and PI3K-related kinase (PIKK) activity contributes to radioresistance in thyroid carcinomas
Natalie Burrows, Joseph Williams, Brian A Telfer, et al.
Plos One
|
August 12, 2016
The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy
Simon J A van Kuijk, Roben G Gieling, Raymon Niemans, et al.
International Journal of Cancer
|
January 7, 2014
A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models
Amy L Adlard, Simon J Dovedi, Brian A Telfer, et al.
Plos One
|
March 3, 2018
High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma
Kenny Kwok-Hei Yu, Jessica T Taylor, Omar N Pathmanaban, et al.
Bioengineering (Basel, Switzerland)
|
May 27, 2026
Deep Learning-Based Tracking of Neurovascular Features Toward Semi-Automated Ultrasound-Guided Peripheral Nerve Blocks by Non-Specialists
Lars A Gjesteby, Alec Carruthers, Joshua Werblin, et al.
Cancer Research Communications
|
December 5, 2022
Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1/S cell cycle transition
Jingwei Zhang, Adam J Pearson, Nitin Sabherwal, et al.
Plos One
|
February 18, 2015
Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself
Cian M McCrudden, Martin G O'Rourke, Kim E Cherry, et al.
Cell Reports
|
June 22, 2022
Oxidative stress from DGAT1 oncoprotein inhibition in melanoma suppresses tumor growth when ROS defenses are also breached
Daniel J Wilcock, Andrew P Badrock, Chun W Wong, et al.
Nature Communications
|
September 26, 2023
PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models
Chun Wai Wong, Christos Evangelou, Kieran N Sefton, et al.
Scientific Reports
|
March 17, 2022
Author Correction: Detection of COVID-19 using multimodal data from a wearable device: results from the first TemPredict Study
Ashley E Mason, Frederick M Hecht, Shakti K Davis, et al.
Page
of 6